Browse the evidence

Higher levels of the satiety hormone leptin are associated with lower salt taste preference during both low-carbohydrate and low-fat diets.

Your body's satiety hormone, leptin, appears to influence how much you prefer salty foods. Higher leptin levels are linked to a lower preference for salt, regardless of whether you are eating low-carb or low-fat. This suggests a biological link between fullness signals and taste preferences.

Maintaining Hemoglobin A1c (HbA1c) levels below 6.0% is a critical intervention for preventing the onset and progression of coronary atherosclerotic heart disease (CHD).

To lower your risk of heart disease, aim to keep your HbA1c below 6%. This involves eating a healthy diet, reducing calories if overweight, and getting at least 150 minutes of moderate exercise per week. Regular screening is essential to catch prediabetes early.

GLP-1 receptor agonists (semaglutide, tirzepatide) cause rapid, significant loss of facial and body subcutaneous fat, leading to skin laxity, volume loss, and accelerated facial aging that requires proactive, multimodal aesthetic intervention.

If you are taking Ozempic or Mounjaro, expect your face to lose volume and your skin to sag. Don't wait until you look 'old' to act. Start aesthetic treatments (like fillers or skin tightening) early in your weight loss journey to maintain your shape and youthfulness.

A structured, multimodal aesthetic intervention protocol (fillers, RF, HIFU, collagen stimulators) initiated early in GLP-1 therapy mitigates facial volume loss and skin laxity.

Work with a cosmetologist to create a personalized plan. Use fillers for volume, RF/HIFU for tightening, and collagen stimulators for skin quality. Start early, not after you've lost all the weight.

GLP-1 receptor agonists (e.g., semaglutide) can support sustained weight stability and may be safely restarted postoperatively in body contouring patients.

If you are using GLP-1 agonists like semaglutide for weight loss, discuss with your doctor whether it is safe to restart or continue them after body contouring surgery. They can help maintain your weight stability and support long-term results.

Adding Subetta® (affinity-purified antibodies against the insulin receptor beta-subunit) and cholecalciferol (Vitamin D) to standard therapy significantly improves glycemic control, lipid profiles, and reduces body mass index in elderly women with type 2 diabetes compared to standard therapy alone.

For elderly women with Type 2 Diabetes who are struggling with weight gain and high blood sugar despite standard medication, adding Vitamin D (4000 IU daily after a loading phase) and Subetta® to their existing regimen (Metformin/Gliclazide) can significantly improve blood sugar, cholesterol, and weight loss without causing dangerous low blood sugar episodes.

Early intensive intervention targeting stringent glycaemic control (HbA1c ≤ 6.5%) and significant weight loss (≥10%) at diagnosis improves long-term prognosis and prevents microvascular complications in younger patients with longer life expectancy.

If you are diagnosed with Type 2 Diabetes and are under 65, do not accept a standard HbA1c target of 7% as the end goal. Work with your doctor to aim for a stricter target (≤ 6.5%) and significant weight loss (10% or more) immediately. This early, intensive approach is critical for preventing long-term complications like eye and kidney damage, especially given your longer life expectancy.

GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors are preferred first-line treatments for patients with Type 2 Diabetes and obesity or cardiovascular disease, respectively, due to their weight-reducing and cardioprotective properties.

If you have Type 2 Diabetes and obesity or heart disease, ask your doctor about GLP-1 receptor agonists or SGLT2 inhibitors. These drugs not only help control blood sugar but also promote weight loss and protect your heart, making them preferred choices over metformin alone for many patients.

Adding luseogliflozin (an SGLT2 inhibitor) to incretin modulator therapy produces an additive glucose-lowering effect, specifically reducing time above range, with the magnitude of benefit being significantly greater in patients consuming high-carbohydrate diets compared to low-carbohydrate diets.

If you are taking an incretin-based diabetes medication (like a GLP-1 agonist or DPP4 inhibitor) and consume a diet high in carbohydrates (e.g., >180g carbs daily), adding luseogliflozin (2.5mg daily) may provide better blood sugar control than adding it to a low-carb diet. This combination appears to work additively, meaning the drugs complement each other to handle the glucose load from carbs more effectively than either might alone in that specific context.

Intermittent fasting improves glycemic control in patients with Type 2 Diabetes, including reductions in fasting glucose, HbA1c, and insulin levels, though it carries a risk of hypoglycemia requiring medication adjustment.

If you have Type 2 Diabetes, intermittent fasting can improve your blood sugar control, but you must work with your doctor to adjust medications like insulin or sulfonylureas to avoid low blood sugar. Studies show that with proper management, IF is safe and can lower HbA1c and fasting glucose levels without severe adverse events.

A remotely delivered, 12-month GLP-1RA (semaglutide) supported weight management program achieves significant weight loss (mean 19.1% of starting weight) in participants who maintain an active subscription, but high withdrawal rates (60.4%) limit generalizability.

If you have obesity and are considering a GLP-1RA like semaglutide, a remote program can help you lose significant weight (around 19% on average) if you stick with it. However, be aware that many people drop out, often due to side effects or cost. To succeed, you need to be committed to the weekly injections and the digital support, and understand that stopping the medication likely leads to weight regain.

Tirzepatide produces significantly greater long-term total body weight loss and fat mass reduction compared to Semaglutide in real-world clinical practice, with effects becoming distinct after 6 months.

If you are choosing between Semaglutide and Tirzepatide for long-term weight management, Tirzepatide offers significantly greater weight loss after 12 months. To maximize results and protect your muscle, you must combine the medication with a program that includes strength training twice a week and a protein intake of 60-90 grams daily.

Females experience significantly greater weight loss than males when treated with incretin-based obesity medications (Semaglutide and Tirzepatide).

If you are male, expect that your weight loss may be slower than that of female peers taking the same medication. This is a known biological response. Do not be discouraged; the medication still provides significant metabolic benefits and fat loss, even if the scale moves slower.

FDA-approved weight loss medications (liraglutide, lorcaserin, naltrexone-bupropion, orlistat, phentermine-topiramate) produce greater weight loss and diabetes risk reduction than placebo, but are associated with higher rates of adverse events and dropout.

If behavioral interventions alone are insufficient, FDA-approved weight loss medications can provide greater weight loss and diabetes risk reduction. However, be prepared for a higher likelihood of side effects and discontinuation. These medications should be used in conjunction with behavioral interventions.

Gradual, individualized dose escalation of GLP-1 receptor agonists is the primary clinical strategy to mitigate gastrointestinal side effects (nausea, vomiting, constipation) and improve treatment persistence in obesity management.

When starting a GLP-1 injection for weight loss, do not rush to the full dose. Start at the lowest possible dose and wait until you feel completely comfortable before asking your doctor to increase it. Eat smaller, low-fat meals and stay hydrated. If you feel nauseous, pause the increase; this is normal and usually goes away.

An 8-week very low carbohydrate ketogenic diet (VLCKD) significantly reduces body fat mass in competitive natural bodybuilders without compromising maximal strength, despite blunting lean mass accretion and reducing anabolic hormones.

If you are a competitive bodybuilder looking to cut fat, an 8-week ketogenic diet can help you lose significant fat mass while maintaining your strength and muscle size. However, do not expect to build new muscle mass on this diet; that requires carbohydrates. Ensure you are eating enough protein (2.5g/kg) and monitoring ketones to stay in ketosis.

Sodium intake between 3 and 5 g/day is associated with the lowest risk of cardiovascular disease and mortality, whereas intake below 3 g/day or above 5 g/day is associated with increased risk.

Aim for a sodium intake of 3 to 5 grams per day (approx. 0.75 to 1.25 teaspoons of salt). This range is associated with the lowest risk of heart disease and death. Avoid extreme restriction below 3 grams, which may increase risk, and excessive intake above 5 grams, which raises blood pressure and risk, especially if you have hypertension.

Consuming carbohydrates last in a mixed meal significantly reduces postprandial glucose and insulin excursions compared to consuming carbohydrates first or all components together in individuals with type 2 diabetes.

If you have type 2 diabetes, try eating your vegetables and protein before your carbohydrates (like bread, rice, or fruit) during meals. In this study, this simple change reduced blood sugar spikes by over 50% compared to eating carbs first. You do not need to cut out carbs; just delay them until the end of your meal. This strategy works by slowing down digestion and boosting hormones that help regulate blood sugar.

EPA and DHA supplementation improves muscle function (strength, torque, EMG) and may increase muscle mass in elderly or wasting conditions, but has unclear effects on muscle protein synthesis in trained young adults.

If you are older or dealing with muscle loss, fish oil might help maintain or build muscle mass when combined with training. If you are a young, trained athlete, fish oil is unlikely to boost your muscle growth or protein synthesis beyond what your training already does.

GLP-1 analogues (Semaglutide and Liraglutide) are recommended for MASLD patients with BMI >27 kg/m2 and CVD risk factors when lifestyle intervention is insufficient, offering significant weight loss and CVD risk reduction.

If lifestyle changes alone haven't reduced your weight or CVD risk, and your BMI is above 27, ask your doctor about GLP-1 analogues like Semaglutide or Liraglutide. These medications can help you lose significant weight (up to 15% with Semaglutide) and improve your heart health.

Achieving a state of nutritional ketosis (β-hydroxybutyrate ≥ 0.3 mmol/L) during a low-carbohydrate diet is associated with greater reductions in visceral adipose tissue, total body fat, and inflammation (CRP), but also with greater loss of lean muscle mass.

If you are doing a low-carb diet, aiming for ketosis (measured by blood ketones ≥ 0.3 mmol/L) may lead to greater fat and visceral fat loss and lower inflammation. However, be aware that this state is also associated with greater lean muscle loss, so maintaining your exercise routine, especially resistance training, is crucial.

The dual GLP-1R/GCGR agonist BI 456906 produces clinically meaningful body weight loss (up to 13.8% over 16 weeks) in adults with overweight/obesity, driven by target engagement at both receptors.

BI 456906 is a once-weekly injection for people with overweight or obesity that works by targeting two hormones (GLP-1 and Glucagon). In early studies, it led to significant weight loss (nearly 14% over 4 months). The main side effects are gastrointestinal (nausea, vomiting), which are common but often manageable. It is designed for people who may not achieve sufficient weight loss with single-target therapies.

In patients with type 2 diabetes duration greater than 10 years, GLP-1RA plus basal insulin fixed-ratio combinations (iDegLira, iGlarLixi) may be numerically more effective for HbA1c reduction than tirzepatide, suggesting tirzepatide is better suited for early-stage disease.

For patients with type 2 diabetes for more than 10 years, GLP-1RA plus basal insulin fixed-ratio combinations may offer better glycemic control than tirzepatide alone, making them a strong option for long-standing disease.

Withholding GLP-1 receptor agonists for at least three half-lives before elective surgery is recommended for weight management patients to minimize retained gastric contents.

For weight loss patients: Check the half-life of your specific drug (e.g., Semaglutide ~7 days, Dulaglutide ~5 days). Stop taking it at least 3 times that duration before your scheduled surgery. For example, if you take Semaglutide (7-day half-life), stop at least 21 days before surgery. Consult your doctor for a bridge plan for blood sugar if applicable.